GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Thoratec Corp (FRA:TL1) » Definitions » Interest Expense

Thoratec (FRA:TL1) Interest Expense : €-0.9 Mil (TTM As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is Thoratec Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Thoratec's interest expense for the three months ended in Jun. 2015 was € -0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2015 was €-0.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Thoratec's Operating Income for the three months ended in Jun. 2015 was € 16.4 Mil. Thoratec's Interest Expense for the three months ended in Jun. 2015 was € -0.0 Mil. Thoratec's Interest Coverage for the quarter that ended in Jun. 2015 was 1,362.67. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Thoratec Interest Expense Historical Data

The historical data trend for Thoratec's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thoratec Interest Expense Chart

Thoratec Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.32 -3.54 - - -0.02

Thoratec Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.88 - - -0.01

Thoratec Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thoratec  (FRA:TL1) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Thoratec's Interest Expense for the three months ended in Jun. 2015 was €-0.0 Mil. Its Operating Income for the three months ended in Jun. 2015 was €16.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2015 was €0.0 Mil.

Thoratec's Interest Coverage for the quarter that ended in Jun. 2015 is calculated as

Interest Coverage=-1* Operating Income (Q: Jun. 2015 )/Interest Expense (Q: Jun. 2015 )
=-1*16.352/-0.012
=1,362.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Thoratec (FRA:TL1) Business Description

Traded in Other Exchanges
N/A
Address
Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Aachen Innovative Solutions GmbH, AbioMed, Inc., Berlin Heart GmbH, HeartWare International Inc., Jarvik Heart, Inc., Maquet Cardiovascular, LLC (a division of Getinge AB), MicroMed Technology, Inc., Sun Medical Technology Research Corporation, SynCardia Systems, Inc., and Terumo Heart, Inc. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.

Thoratec (FRA:TL1) Headlines

No Headlines